Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone267-440-4200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.48 million
Profitability
Miscellaneous
Employees281
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals's stock reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals Inc (NASDAQ:INO) posted its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.02. The biopharmaceutical company had revenue of $0.14 million for the quarter, compared to analyst estimates of $4.69 million. Inovio Pharmaceuticals had a negative net margin of 1,560.70% and a negative return on equity of 142.10%. During the same period in the prior year, the firm earned ($0.07) earnings per share. View Inovio Pharmaceuticals' Earnings History.
When is Inovio Pharmaceuticals' next earnings date?
What price target have analysts set for INO?
5 brokers have issued 12-month price objectives for Inovio Pharmaceuticals' stock. Their predictions range from $3.62 to $13.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $8.1240 in the next twelve months. This suggests a possible upside of 253.2% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals.
What is the consensus analysts' recommendation for Inovio Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals.
What are Wall Street analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We are maintaining our Buy rating of EDAP TMS and our 12-month price target of $6.50 per diluted ADS. We derived our price target based on the average of two valuation methods: 1) price-earnings multiple using 25x 2026 EPS estimate discounted at 12%; and 2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2026 free cash flow estimate at a 12% discount rate. (1) commercial; (2) regulatory; (3) currency; (4) reimbursement; and (5) intellectual property." (6/11/2019)
- 2. According to Zacks Investment Research, "Inovio’s earnings and revenues missed estimates in the first quarter of 2019. The company’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Roche, Regeneron and AstraZeneca, which helps the company with their expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio and its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares have underperformed the industry year to date." (5/28/2019)
- 3. Maxim Group analysts commented, "Inovio and its collaborators from The Wistar Institute presented positive preclinical data from its novel dBiTE (DNA-Encoded Bi-specific T Cell Engager) program at the American Association for Cancer Research (AACR) annual meeting." (4/3/2019)
Has Inovio Pharmaceuticals been receiving favorable news coverage?
Media coverage about INO stock has been trending positive recently, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Inovio Pharmaceuticals.
Are investors shorting Inovio Pharmaceuticals?
Inovio Pharmaceuticals saw a drop in short interest in July. As of July 15th, there was short interest totalling 11,124,300 shares, a drop of 5.2% from the June 15th total of 11,738,900 shares. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is presently 10.9 days. Currently, 12.5% of the shares of the company are sold short. View Inovio Pharmaceuticals' Current Options Chain.
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Anika Therapeutics (ANIK), Cerus (CERS), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), SurModics (SRDX), Antares Pharma (ATRS), Intersect ENT (XENT), SI-Bone (SIBN), Orthopediatrics (KIDS), OraSure Technologies (OSUR), MiMedx Group (MDXG), Alphatec (ATEC), GenMark Diagnostics (GNMK), Utah Medical Products (UTMD) and Westaim (WEDXF).
What other stocks do shareholders of Inovio Pharmaceuticals own?
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)
- Mr. Peter D. Kies, Chief Financial Officer (Age 56)
- Dr. Jacqueline E. Shea, COO & Exec. VP (Age 53)
- Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)
- Dr. Laurent M. Humeau, Chief Scientific Officer & Exec. VP (Age 52)
Who are Inovio Pharmaceuticals' major shareholders?
Inovio Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.86%), Wasatch Advisors Inc. (6.87%), Nikko Asset Management Americas Inc. (4.98%), Sumitomo Mitsui Trust Holdings Inc. (4.98%), Vanguard Group Inc. (4.96%) and ARK Investment Management LLC (4.03%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Which major investors are selling Inovio Pharmaceuticals stock?
INO stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Royal Bank of Canada, Wells Fargo & Company MN, Invesco Ltd., Defender Capital LLC. and Northern Trust Corp. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim and Peter Kies. View Insider Buying and Selling for Inovio Pharmaceuticals.
Which major investors are buying Inovio Pharmaceuticals stock?
INO stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., ARK Investment Management LLC, Wasatch Advisors Inc., JPMorgan Chase & Co., BlackRock Inc., Jane Street Group LLC and Vanguard Group Inc.. View Insider Buying and Selling for Inovio Pharmaceuticals.
How do I buy shares of Inovio Pharmaceuticals?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of INO stock can currently be purchased for approximately $2.30.
How big of a company is Inovio Pharmaceuticals?
Inovio Pharmaceuticals has a market capitalization of $227.76 million and generates $30.48 million in revenue each year. The biopharmaceutical company earns $-96,970,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.View Additional Information About Inovio Pharmaceuticals.
What is Inovio Pharmaceuticals' official website?
How can I contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
